Form4insider filings, from the source

SEC Form 4 · accession 0001193805-16-004027

Vanda Pharmaceuticals Inc. · VNDA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
DEERFIELD MANAGEMENT CO
10% Owner · Other
Deerfield Mgmt L.P.
10% Owner · Other
DEERFIELD PARTNERS, L.P.
10% Owner · Other
James E Flynn
10% Owner · Other
Period of report
Sep 22, 2016
Accepted (ET)
Sep 26, 2016 · 5:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001347178

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F3,F4Sep 22, 2016S119,690$16.239D1,873,108IThrough Deerfield Partners, L.P.
Common StockF1,F3,F4Sep 22, 2016S152,334$16.239D2,383,955IThrough Deerfield International Master Fund, L.P.
Common StockF1,F3,F4Sep 22, 2016S68,940$16.239D850,778IThrough Deerfield Special Situations Fund, L.P.
Common StockF2,F3,F4Sep 23, 2016S273,632$16.707D1,599,476IThrough Deerfield Partners, L.P.
Common StockF2,F3,F4Sep 23, 2016S348,258$16.707D2,035,697IThrough Deerfield International Master Fund, L.P.
Common StockF2,F3,F4Sep 23, 2016S157,607$16.707D693,171IThrough Deerfield Special Situations Fund, L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Editas Medicine, Inc. filed with the Securities and Exchange Commission on February 2, 2016 by Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt HIF, L.P., Deerfield Private Design Fund III, L.P. and James E. Flynn.